The Food and Drug Administration approved a multiple-sclerosis drug called Ocrevus, the first treatment for the most severe type of the disease, known as primary progressive MS. The medicine, from Genentech Inc., is generically called ocrelizumab. Primary progressive MS affects about 15% of the estimated 2.3 million MS patients in the world. The patients with this severe type have watched for years as more than a dozen other...

Source: Wall Street Journal March 29, 2017 01:52 UTC